Pharma Boulevard
ActiveSummary
The computed 12-month bankruptcy probability of Pharma Boulevard is 2.0% (moderate). The 2025 annual accounts show equity of €491,905 and a net result of €181,302. Equity is growing by about 58% per year across the filed financial years. Its solvency ranks better than 33% of 12,672 sector peers (NACE 47, financial year 2025). The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
30-09
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 61 days late
2025
30-09
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format · 61 days late
2024
31-12
Financial
Highest result from 2021 to 2025net €187,805 ▲148%
Net result €187,805, the highest in the series.
31-12
Financial
Equity above €200,000equity €385,603 ▲94.9%
3 profitable years in a row build equity to €385,603.
30-09
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format · 61 days late
2023
31-12
Financial
Equity above €150,000equity €197,798 ▲61.9%
2 profitable years in a row build equity to €197,798.
13-10
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 74 days late
2022
31-12
Financial
Back to profitnet €29,199
Net result €29,199 after one loss-making year.
31-12
Financial
Equity above €100,000equity €122,142 ▲31.4%
Equity rises from €92,942 to €122,142.
31-10
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format · 92 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.